Premium
Analysis of fexofenadine in pharmaceutical formulations using tris(1,10‐phenanthroline)–ruthenium(II) peroxydisulphate chemiluminescence system in a multichip device
Author(s) -
Al Lawati Haider A. J.,
Al Dahmani Zeiyana M.,
Suliman Fakhr Eldin O.,
Al Kindy Salma M. Z.,
AlLawati Ali M.
Publication year - 2011
Publication title -
luminescence
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.428
H-Index - 45
eISSN - 1522-7243
pISSN - 1522-7235
DOI - 10.1002/bio.1310
Subject(s) - chemiluminescence , ruthenium , phenanthroline , fexofenadine , tris , chemistry , combinatorial chemistry , nuclear chemistry , photochemistry , chromatography , organic chemistry , pharmacology , medicine , catalysis , biochemistry
ABSTRACT A simple, rapid and sensitive method has been developed for the analysis of fexofenadine (FEX) in pharmaceutical formulations, using a tris(1,10‐phenanthroline)–ruthenium(II) [Ru(phen) 3 2+ ] peroxydisulphate chemiluminescence (CL) system in a multichip device. Various parameters that influence the CL signal intensity were optimized. These included pH, flow rates and concentration of reagents used. Under optimum conditions, a linear calibration curve in the range 0.05–5.0 µg/mL was obtained. The detection limit was found to be 0.001 µg/mL. The procedure was applied to the analysis of FEX in pharmaceutical products and was found to be free from interference from concomitants usually present in these preparations. Copyright © 2011 John Wiley & Sons, Ltd.